Peer Review

Peer Review: Plotting US moves, Zealand Pharma poaches Alnylam’s Emmanuel Dulac as new CEO

Concluding a four-month search for Britt Meelby Jensen’s replacement, Zealand Pharma has wooed top Alnylam exec Emmanuel Dulac to take the helm as its new CEO.

Dulac’s most recent role was chief commercial officer at Alnylam, where he was brought in to build a global commercial infrastructure in two years before the biotech notched a long-awaited approval for its groundbreaking RNAi medicine.

That job took him to Basel, Switzerland, with frequent trips to the Boston area. Adding that to his previous stints at Novartis and Shire as well as board seat at Proteostasis, Dulac brings years of experience working in both Europe and North America.

All that will come in handy as Copenhagen-based Zealand puts a foot down in the US. A Nasdaq biotech class of 2017, Zealand has a pipeline of peptide-based medicines that it’s pushing in orphan or rare indications.

More Peer Review

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,300+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->